首页> Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie> MiR-183-5p is required for non-small cell lung cancer progression by repressing PTEN.

MiR-183-5p is required for non-small cell lung cancer progression by repressing PTEN.

导出 LinkOut

翻译打印收藏纠错

第一作者： Huimin,Wang

第一单位： Lab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai 200444, China.

作者： Huimin,Wang ^[1] ; Zhongliang,Ma ^[1] ; Xiaomin,Liu ^[1] ; Caiyan,Zhang ^[1] ; Yanping,Hu ^[2] ; Lei,Ding ^[1] ; Pengfei,Qi ^[1] ; Ju,Wang ^[3] ; Shengdi,Lu ^[4] ; Yanli,Li ^[5]

作者单位： Lab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai 200444, China. ^[1] School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China. ^[2] Lab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai 200444, China; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. ^[3] Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Xuhui District, Shanghai 200233, China. Electronic address: lushendi0828@163.com. ^[4] Lab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai 200444, China. Electronic address: liyanli@shu.edu.cn. ^[5]

关键词 Non-small cell lung cancer PTEN Tumorigenesis miR-183-5p